Drugs that contain Bexagliflozin

1. List of Brenzavvy drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8802637 THERACOSBIO Benzylbenzene derivatives and methods of use
Aug, 2028

(5 years from now)

US7838499 THERACOSBIO Benzylbenzene derivatives and methods of use
Jan, 2029

(5 years from now)

US10981942 THERACOSBIO Crystalline form of benzylbenzene SGLT2 inhibitor
Jun, 2031

(8 years from now)

US8987323 THERACOSBIO Crystalline form of benzylbenzene SGLT2 inhibitor
May, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8106021 THERACOSBIO Benzylbenzene derivatives and methods of use
Aug, 2028

(5 years from now)

US10533032 THERACOSBIO Crystalline form of benzylbenzene SGLT2 inhibitor
Jul, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 20, 2028

NCE-1 date: 2027-01-20

Market Authorisation Date: 20 January, 2023

Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

Dosage: TABLET;ORAL

More Information on Dosage

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic